Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe
Delphine Ammar(Astellas Pharma (Netherlands)), Jacquelyn Awigena-Cook(Bristol-Myers Squibb (Germany)), Anne Galy(Centre National de la Recherche Scientifique), Nina Worel(Medical University of Vienna), Ulrike Philippar(Janssen (Belgium)), Felipe Prósper(Institute of Human Genetics), Jan Brülle(Hans Böckler Foundation), Franco Locatelli(Bambino Gesù Children's Hospital), Andreas Kremer(Erasmus MC), Marie José Kersten(Hovon), Norbert Ifrah(Institut National du Cancer), Ulrike Koehl(Leipzig University), Kristin Reiche(German Research Centre for Artificial Intelligence), Robin Doeswijk(European Hematology Association), Martina Schüßler‐Lenz(Paul Ehrlich Institut), Javier Briones(Hospital de Sant Pau), Maik Luu(Klinik und Poliklinik für Psychosomatik und Psychotherapie), Christian J. Buchholz(Goethe University Frankfurt), Jürgen Kuball(Utrecht University), Emmanuel Donnadieu(Institut Cochin), Carmen Sanges(Augenklinik Universitätsklinikum Würzburg), Dirk H. Busch(German Center for Infection Research), Bruno Quesnel(Université de Lille), Monica Casucci(Vita-Salute San Raffaele University), Chiara Bonini(Vita-Salute San Raffaele University), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Paul Franz(Mount Sinai Medical Center), Christophe Ferrand(Centre National de la Recherche Scientifique), David Henderson(Bayer (Germany)), Leopold Sellner(National Center for Tumor Diseases), Frederick W. Thielen(University Medical Center Freiburg), Inga Schapitz(Bayer (Germany)), Maria Luisa D'Amore(Bambino Gesù Children's Hospital), Ulf Grawunder(University of Würzburg), Michael Hudecek(Augenklinik Universitätsklinikum Würzburg), Maria Thermeli(Lymphoma Study Association), Carin Uyl-de Groot(Erasmus University Rotterdam), Maria Quaranta(Luxembourg Institute of Science and Technology), Judith Theelen(Miltenyi Biotec (Germany)), Bernd Schröder(Miltenyi Biotec (Germany))
Cited by 0
Related Papers
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
|Cell|2020|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
|Journal of Clinical Investigation|2012|1.1k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k